Introduction
============

Cancer has been recognized as one of the leading causes of death worldwide. According to the estimation of GLOBOCAN, \~12.7 million new cases and 7.6 million deaths of cancer had occurred in 2008.[@b1-ott-9-001] Cancer is a multifactor disease resulting from the combined effect of genetic susceptibility and environmental factors.[@b2-ott-9-001]--[@b4-ott-9-001] The role of inflammation in carcinogenesis is a pivotal issue. Previous studies have demonstrated that inflammation-associated molecules are associated with a majority of cancer types, and these molecules are activated by various elements related to environment and lifestyle.[@b5-ott-9-001]

Interleukin-1 (IL-1) family consists of the three key proinflammatory cytokines, including IL-1A, IL-1B, and IL-1 receptor antagonist (IL-1RA). Some studies have suggested that IL-1 contributes to tumor proliferation, angiogenesis, tumor invasion, metastases, and patterns of interactions between malignant cells and the host's immune system.[@b6-ott-9-001]--[@b9-ott-9-001] IL-1A is involved in numerous immune responses and inflammatory process, and has been reported to play an important role in human carcinogenesis.[@b10-ott-9-001]

The *IL-1A* gene is located on chromosome 2q14 and has some identified polymorphisms. An insertion/deletion (Ins/Del) polymorphism (rs3783553, TTCA/-) located in the 3′ untranslated regions of *IL-1A*, has been suggested to regulate the expression levels of IL-1A through disrupting a binding site for miR-122 and miR-378.[@b11-ott-9-001] In addition, early epidemiology studies have reported the association between *IL-1A* rs3783553 polymorphism and the risk of cancer, including cervical carcinoma, oral squamous cell carcinoma, prostate cancer, ovarian cancer, gastric cancer, papillary thyroid carcinoma, hepatocellular carcinoma, and nasopharyngeal carcinoma.[@b11-ott-9-001],[@b12-ott-9-001]--[@b20-ott-9-001] However, results from the published studies remain conflicting rather than conclusive. Therefore, the present study authors performed a meta-analysis to clarify the effects of *IL-1A* rs3783553 polymorphism on cancer risk.

Materials and methods
=====================

Publication search
------------------

The present study authors systematically searched the PubMed, Web of knowledge, and Chinese National Knowledge Infrastructure databases. The following medical subject headings terms and free words were used: "interleukin-1A" or "IL-1A" and "polymorphism" or "variant" and "tumor" or "cancer" or "carcinoma". The last search was updated on September 2, 2015. The search was limited to human, and no language restrictions were applied. Additional studies were identified by a hand search of the references of original studies.

Inclusion and exclusion criteria
--------------------------------

The included studies conformed to the following criteria: 1) a case--control study, 2) evaluation of the *IL-1A* rs3783553 polymorphism and cancer susceptibility, and 3) the inclusion of the detailed data that determine genotype distributions. The major exclusion criteria were: 1) a lack of data regarding the *IL-1A* rs3783553 polymorphism, 2) the inclusion of duplicate data, and 3) case reports or review articles.

Data extraction
---------------

Information was carefully extracted from all eligible studies by two independent investigators (Ling Ma and Ning Zhou). The following data were collected from each study: the first author's name, year of publication, country of origin, ethnicity, genotyping method, *P*-values from the Hardy--Weinberg equilibrium test for the control group, and genotype and allele frequencies among the cases and controls. All disagreements were discussed and resolved with consensus.

Statistical analysis
--------------------

Hardy--Weinberg equilibrium among controls for each study was assessed using Pearson's *χ*^2^ test. The strength of association between *IL-1A* rs3783553 polymorphism and the risk of cancer was estimated for each study by crude odds ratio (OR) and corresponding 95% confidence interval (CI). Four models were conducted: dominant model (Ins/Ins + Ins/Del vs Del/Del), heterozygote comparison (Ins/Del vs Del/Del), homozygote comparison (Ins/Ins vs Del/Del), recessive model (Ins/Ins vs Ins/Del + Del/Del), and allele model (Ins vs Del). Summary ORs and corresponding 95% CIs were estimated by the fixed-effects model or the random-effects model. The *χ^2^*-test-based Q statistic test was performed to assess between-study heterogeneity. The effect of heterogeneity was quantified according to the *I^2^* value. When a significant Q test (*P*\<0.05) or *I^2^*\>50% indicated heterogeneity across studies, the random-effects model was used. Otherwise, the fixed-effects model was applied. Stratification analyses on cancer type and ethnicity were performed. Sensitivity analysis was tested by sequentially omitting one individual study at a time. Finally, the Begg's funnel plot and Egger's test were adopted to assess potential publication bias. All statistical analyses were implemented by the STATA Software (version 9.0, Stata Corp., College Station, TX, USA).

Results
=======

Eligible studies
----------------

The study selection procedure is shown in [Figure 1](#f1-ott-9-001){ref-type="fig"}. A total of 77 articles were identified that were relevant to the search terms. After screening the titles and abstracts, 64 articles were excluded for being irrelevant to *IL-1A* polymorphisms and cancers risk. After reading the full texts of the 13 articles, three articles were excluded for being irrelevant to the investigated polymorphism. Finally, ten studies were left for data extraction. The main characteristics of the eligible studies are presented in [Tables 1](#t1-ott-9-001){ref-type="table"} and [2](#t2-ott-9-001){ref-type="table"}. A total of 4,514 cancer cases and 6,689 controls were included for data synthesis. In addition, nine studies were conducted in Asian populations and only one in European population.

Quantitative synthesis
----------------------

As shown in [Table 3](#t3-ott-9-001){ref-type="table"} and [Figure 2](#f2-ott-9-001){ref-type="fig"}, meta-analysis of the total studies suggested that there was a significant association between the *IL-1A* rs3783553 polymorphism and cancer risk (Ins/Ins + Ins/Del vs Del/Del: OR =0.79, 95% CI =0.67--0.92; Ins/Ins vs Del/Del: OR =0.61, 95% CI =0.47--0.79; Ins/Ins vs Ins/Del + Del/Del: OR =0.67, 95% CI =0.55--0.83; Ins vs Del: OR =0.81, 95% CI =0.72--0.92). The subgroup analysis according to ethnicity suggested that *IL-1A* rs3783553 polymorphism was significantly associated with cancer risk in Asian populations (Ins/Ins + Ins/Del vs Del/Del: OR =0.81, 95% CI =0.69--0.95). Subgroup analysis by cancer type showed a significant association between *IL-1A* rs3783553 polymorphism and cervical carcinoma (Ins/Ins vs Del/Del: OR =0.51, 95% CI =0.34--0.76; Ins/Ins vs Ins/Del + Del/Del: OR =0.52, 95% CI =0.35--0.78).

Sensitivity analysis and publication bias
-----------------------------------------

After sequentially excluding each case--control study, statistically similar results were obtained ([Figure 3](#f3-ott-9-001){ref-type="fig"}). This suggests that the data of our meta-analysis are relatively stable and credible. In addition, Begg's funnel plot and Egger's test were performed to assess the publication bias of our meta-analysis. As shown in [Figure 4](#f4-ott-9-001){ref-type="fig"}, the shape of the funnel plot appeared to be symmetrical. The Egger's test also showed no publication bias.

Discussion
==========

To reveal a small effect of the polymorphisms on cancer risk, a single study might have low statistical power to detect a true association, particularly for studies with small sample size. Meta-analysis is considered as a powerful tool to summarize inconclusive results from different studies and produce a single estimate with enhanced precision. In the current meta-analysis, we found that the *IL-1A* rs3783553 polymorphism was statistically significantly associated with decreased risk of cancer under dominant model, homozygote comparison, recessive model, and allele model. In addition, stratification analyses by ethnicity and tumor type showed significant association in Asian populations and cervical carcinoma. Although previous functional experiment has shown that *IL-1A* rs3783553 polymorphism can regulate the expression levels of IL-1A through disrupting a binding site for miR-122 and miR-378 in hepatocellular carcinoma. However, whether the SNP has identical function in different cancer types needs to be further investigated.[@b11-ott-9-001]

To the best of our knowledge, this was the first meta-analysis providing comprehensive insights into the effects of *IL-1A* rs3783553 polymorphism on cancer risk. However, some limitations of this meta-analysis study should be considered. First, due to lack of original data, we could not evaluate the potential interactions of gene--gene and gene--environment. Second, the number of the eligible studies was small, which may result in potential publication bias, in spite of no significant publication bias in our meta-analysis. Finally, this meta-analysis included data mainly from Asian populations, so that, the results are applicable to specific ethnic groups.

Conclusion
==========

The current meta-analysis results suggest that the *IL-1A* rs3783553 polymorphism is associated with susceptibility to cancer. However, larger well-designed studies are warranted to validate these findings.
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###### 

General characteristics of studies included in the meta-analysis

  First author                  Year   Country                      Ethnicity   Cancer type                        Genotyping methods   Cases   Controls
  ----------------------------- ------ ---------------------------- ----------- ---------------------------------- -------------------- ------- ----------
  Huang et al[@b13-ott-9-001]   2015   People's Republic of China   Asian       Cervical squamous cell carcinoma   PCR                  235     314
  Zhang et al[@b14-ott-9-001]   2015   USA                          European    Oral squamous cell carcinoma       PCR-PAGE             325     335
  Liao et al[@b15-ott-9-001]    2014   People's Republic of China   Asian       Prostate cancer                    PCR-PAGE             131     229
  Zhang et al[@b16-ott-9-001]   2014   People's Republic of China   Asian       Epithelial ovarian cancer          PCR-PAGE             301     240
  Zeng et al[@b17-ott-9-001]    2014   People's Republic of China   Asian       Gastric cancer                     PCR                  207     381
  Pu et al[@b12-ott-9-001]      2014   People's Republic of China   Asian       Cervical carcinoma                 PCR-PAGE             319     424
  Gao et al[@b18-ott-9-001]     2014   People's Republic of China   Asian       Papillary thyroid carcinoma        PCR                  273     509
  Du et al[@b19-ott-9-001]      2014   People's Republic of China   Asian       Hepatocellular carcinoma           Quantitative PCR     998     2,288
  Yang et al[@b20-ott-9-001]    2011   People's Republic of China   Asian       Nasopharyngeal carcinoma           PCR                  248     296
  Gao et al[@b11-ott-9-001]     2009   People's Republic of China   Asian       Hepatocellular carcinoma           PCR-PAGE             1,477   1,673

**Abbreviation:** PCR-PAGE, polymerase chain reaction-polyacrylamide gel electrophoresis.

###### 

Genotype and allele frequencies of *IL-1A* rs3783553 polymorphism in cases and controls

  First author                  Cases   Controls   *P*~HWE~                                                       
  ----------------------------- ------- ---------- ---------- ----- ------- ----- ------- ------- ------- ------- ------
  Huang et al[@b13-ott-9-001]   13      134        88         160   310     33    147     134     213     415     0.43
  Zhang et al[@b14-ott-9-001]   179     179        146        N/A   N/A     223   223     112     N/A     N/A     N/A
  Liao et al[@b15-ott-9-001]    8       53         70         69    193     30    118     81      178     280     0.20
  Zhang et al[@b16-ott-9-001]   29      126        146        184   418     36    110     94      182     298     0.68
  Zeng et al[@b17-ott-9-001]    15      102        90         132   282     51    183     147     285     477     0.62
  Pu et al[@b12-ott-9-001]      26      140        153        192   446     60    201     163     321     527     0.88
  Gao et al[@b18-ott-9-001]     29      132        112        190   356     56    242     211     354     664     0.28
  Du et al[@b19-ott-9-001]      113     451        434        677   1,319   259   1,027   1,002   1,545   3,031   0.86
  Yang et al[@b20-ott-9-001]    28      106        114        162   334     56    132     108     244     348     0.17
  Gao et al[@b11-ott-9-001]     149     676        652        974   1,980   231   815     627     1,277   2,069   0.19

**Abbreviations:** IL-IA, interleukin-IA; HWE, Hardy--Weinberg equilibrium; Ins/Del, insertion/deletion; NA, not available.

###### 

Summary odds ratios relations between the *IL-1A* rs3783553 polymorphism and cancer risk

  Comparison                Subgroup                   *I^2^* (%)   [\*](#tfn3-ott-9-001){ref-type="table-fn"}*P*-value   OR (95% CI)          
  ------------------------- -------------------------- ------------ ----------------------------------------------------- ------------- ------ -------------------
  Dominant model            Overall                    69.3         0.001                                                 0.002         0.32   0.79 (0.67--0.92)
                            Cervical carcinoma         85.4         0.009                                                 0.76                 0.91 (0.50--1.65)
                            Hepatocellular carcinoma   86.6         0.006                                                 0.36                 0.88 (0.66--1.16)
                            Asian                      69.1         0.001                                                 0.009                0.81 (0.69--0.95)
  Heterozygote comparison   Overall                    59.6         0.011                                                 0.06          0.08   0.87 (0.75--1.01)
                            Cervical carcinoma         85.2         0.009                                                 0.98                 1.01 (0.55--1.86)
                            Hepatocellular carcinoma   78.6         0.031                                                 0.37                 0.90 (0.71--1.14)
  Homozygote comparison     Overall                    63.4         0.005                                                 0.001         0.10   0.61 (0.47--0.79)
                            Cervical carcinoma         0.0          0.552                                                 0.001                0.51 (0.34--0.76)
                            Hepatocellular carcinoma   87.2         0.005                                                 0.33                 0.79 (0.49--1.27)
  Recessive model           Overall                    50.1         0.042                                                 0.001         0.11   0.67 (0.55--0.83)
                            Cervical carcinoma         0.0          0.86                                                  0.001                0.52 (0.35--0.78)
                            Hepatocellular carcinoma   78.9         0.03                                                  0.31                 0.83 (0.59--1.18)
  Allele model              Overall                    71.0         0.001                                                 0.001         0.09   0.81 (0.72--0.92)
                            Cervical carcinoma         76.6         0.039                                                 0.32                 0.84 (0.59--1.18)
                            Hepatocellular carcinoma   89.0         0.003                                                 0.34                 0.90 (0.71--1.13)

**Notes:**

*P*~H~, *P*-value of heterogeneity test; *P*~Z~, *P*-value of Z test; *P*~E~, *P*-value of Egger's test.

**Abbreviations:** CI, confidence interval; IL-IA, interleukin-IA; OR, odds ratio.
